Wells Fargo cuts RxSight target on lower estimates
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Wells Fargo lowered its RxSight (NASDAQ: RXST) price target to $6.00 from $9.00 while keeping an Equal Weight rating, citing reduced revenue and EPS estimates for fiscal 2026 and 2027. The cut follows third-quarter 2026 results that missed revenue expectations, with sales down year over year on lower procedure volume and competitive pressure.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.